Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx zakázaných látek x metod xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu.

S xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx x prezident xxxxxxxxx xxxxxxxx listinu x xxxxxxx xxxx Přílohy X Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost x souladu s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. června 2024 x xxxxxxxxx Xxxxxxx X xxx xxx 2023, xxxxxxx od 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 x xxxx vyhlášena xxx č. 32/2023 Sb. m. s.

Xxxxxxxx znění Přílohy X xxx xxx 2024 x xxxx xxxxxxx xx xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. JUDr. Xxxxxx, Xx.X., XX.X., x. r.

vrchní ředitel xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx xx povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x metod bude xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění x xxxxxxxxxx.

Xxxx xxxx uvedeny xxxxxxx xxxxx používané x xxxxx Seznamu xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx neschválila jiné xxxxxx, je období Xxx xxxxxxx x xxxxxx xxxxxxx začínajícím xxxxx xxxx xxxxxxx (xx 23:59 xxxxx) x den xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, xx xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Mimo xxxxxx, jak je xxxxxxxxxx x Kodexu.

Specifické x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx účely xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Specifickými xxxxxxx, x výjimkou xxxx xxxxxxxxxx v Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Žádná Xxxxxxxx metoda xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Xxxxxxx xxxxxxxxx označena xxxx Xxxxxxxxxx xxxxxx.“ Podle xxxxxxxxx x xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx xxxxxxx x článku 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx xxxxxxxx xxxx xxxx nebezpečné xxx xxxx xxxxxxxxx xxxxx nebo xxxxxx. Xxx xxxxx x xxxxx x xxxxxx, xxxxx Sportovec xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx xxxxx xxx ke zlepšení xxxxxxxxxxx výkonu.“

Návykové xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx jako xxxxx, xxxxx xxxx xxxx xxxxxx xxxxxxxx z xxxxxx jejich xxxxxxx xxxxxxxxxx ve společnosti xxxx rámec sportu. Xxxx Návykové látky xxxx xxxxxxxxxx xxxx xxxxx: kokain, xxxxxxxxx (xxxxxx), methylendioxymetamfetamin (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (THC).

S0 XXXXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Jakákoliv xxxxxxxxxxxxxx látka, na xxxxxx xx xxxxxxxxxx xxxxx x následujících xxxxxx Xxxxxxx a xxxxx není x xxxxxxxx době xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pro xxxxxxx použití x xxxx (xxxx. xxxxxx x předklinickém xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx byl xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

Xxxx xxxxx zahrnuje xxxxx xxxxxxx látek, xxxx xxxx XXX-157, 2,4-dinitrofenol (XXX) x aktivátory xxxxxxxxx (např. Reldesemtiv x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX STÁLE (PŘI XXXXXXX I MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx zakázány.

S1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx xxxxxxxxx podání, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion)		•	furazabol (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)
•	1-androsteron (3ɑ-hydroxy-5a-androst-1-en-17-on)		•	gestrinon
•	1-epiandrosteron (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)		•	mesterolon
•	4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion)		•	metandriol
•	7ɑ-hydroxy-DHEA		•	metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (androst-4-en-3,17-dion)		•	norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (androsta-1,4-dien-3,17-dion)		•	oxandrolon
•	calusteron		•	oxymesteron
•	klostebol		•	oxymetolon
•	danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)		•	prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

X1.2. XXXXXXX ANABOLICKÉ LÁTKY

Mimo xxxx včetně:

Clenbuterol, osilodrostat, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů [SARM, xxxx. andarin, enobosarm (xxxxxxx), XXX-4033 (ligandrol), XXX140, X-23 a XX-11], xxxxxxx a xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxxxx látky.

Následující látky x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X LÁTKY XXXXXXXXXXX XXXXXXXXXXX

Xxxx jiné včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx na EPO, [xxxx. XXX-Xx, metoxypolyetylenglykol-epoetin xxxx (XXXX)]; EPO- xxxxxxxxx xxxxxxxxxx a xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii vyvolávajícího xxxxxxx (XXX), např. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; molidustat (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (AKB-6548); xenon.

S2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Xxxxxxxx xxxxxxxxx opravného xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX XXXXXXX A XXXXXX XXXXXXXXXX FAKTORY

S2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, mimo xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (CG),

• luteinizační xxxxxx (LH),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a jeho xxxxxxxxxxx xxxxxxx (např. xxxxxxxxx, deslorelin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny x xxxxxx uvolňující xxxxxxx, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.

X2.2.3 Růstový xxxxxx (XX), xxxx xxxxxxx x xxxxxxxxx, mimo xxxx včetně:

• analogy xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,

• fragmenty xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176–191.

S2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x tesamorelin,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x jejich xxxxxxxx [např. anamorelin, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, lenomorelin (xxxxxxx), xxxxxxxxxxx a tabimorelin],

• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. alexamorelin, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX FAKTORY X MODULÁTORY RŮSTOVÝCH XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx analogy

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)

• xxxxxxxx-β4 x xxxx deriváty, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX)

x xxxxx růstové faktory xxxx modulátory růstových xxxxxxx ovlivňující xxxxxxx/xxxxxxxxx xxxxxxxx xx svalech, xxxxxxxx nebo xxxxxx, xxxxxxxxxxxxx, využití energie, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx svalových xxxxxx.

X3 BETA-2 AGONISTÉ

ZAKÁZANÉ XXXXX (PŘI SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.

Všichni xxxxxxxxxx x neselektivní xxxx-2 xxxxxxxx xxxxxx všech xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 hodin xx jakékoliv xxxxx;

• xxxxxxxxx formoterol: maximálně xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 hodin;

• xxxxxxxxx xxxxxxxxxx: maximálně 25 xxxxxxxxxx za 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx salbutamolu x xxxx v xxxxxxxx xxxxxx než 1000 xx/xx xxxx xxxxxxxxxxx v xxxxxxxx xxxxxx než 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx látky x xxxx xxxxxxxxxx xx Xxxxxxxxx laboratorní nález (XXX), pokud Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (inhalační) xx do výše xxxxxxx maximální dávky.

S4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX I XXXX XXXXXX)

Xxxxxxxx látky xx xxxxxxx S4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx zařazené xx xxxx X4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx modulátory xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx včetně:

•	2-androstenol (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX LÁTKY [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx A		•	inhibitory xxxxxxxxxx, např.:
•	konkurenty receptoru xxxxxxxx IIB, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx expresi myostatinu
	- xxxxxxx receptory xxxxxxxx (xxxx. ACE-031)			- xxxxxxxx xxxxxx myostatin (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx)
•	xxxxxxxxxx xxxxx receptoru aktivinu XXX (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (např. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. METABOLICKÉ XXXXXXXXXX

X4.4.1 xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516) x agonisté Xxx-xxxɑ , např. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 DIURETIKA X XXXXXXXXX LÁTKY

ZAKÁZANÉ STÁLE (XXX XXXXXXX I XXXX SOUTĚŽ)

Všechny zakázané xxxxx v této xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx diuretika a xxxxxxxxx látky, včetně xxxxx optických xxxxxxx, xxxx. d- x x-, xxxx xxxxxxxx.

Xxxx xxxx včetně:

•  Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x hydrochlorothiazid; xxxxxxxxx; triamteren;

• Vaptany, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Plazmatické xxxxxxxxx xxxxxxxx intravenózně, např.:

albumin, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Desmopresin;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx oftalmologické xxxxxxxx xxxxxxxxxx karboanhydrázy (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx xxxxxx felypresinu x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo případně Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx (kromě lokálního xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx v xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxx xxxxxxxxxx Terapeutickou xxxxxxx (XX) na tuto xxxxx navíc k xx, xxxxx xxx xxxx xxxxxxx na xxxxxxxxxx xxxx jinou xxxxxxxxx látku.

ZAKÁZANÉ XXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx s xxxxxxxx xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX X XXXX A KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx následující:

M1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, allogenní (homologní) xxxx heterologní xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx do oběhového xxxxxxx x xxxxxxxx xxxxxxxx plazmy xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy provedené x registrovaném odběrovém xxxxxx.

X1.2. Umělé xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (RSR13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx xxxxxxxx xx xxxx hemoglobinu x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx intravaskulární manipulace x krví nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx o podvod xx účelem xxxxxxx xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx a/nebo úprava Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více než xxxxxx 100 ml xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

X3.1. Použití xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx sekvence xxxxxx x/xxxx xxxxxxx xxxx jakýmkoliv mechanismem. Xx mimo xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Xxxxxxx normálních xxxx geneticky xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky x xxxxxxxx xxxxx xxxxxxxxx x S6.A, xxx jsou Nespecifické xxxxx.

Xxxxxxxx xxxxx x xxxx sekci: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx všech xxxxxxxxx xxxxxxx, např. x- x x-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx včetně:

•	2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, metylhexanamin)		•	heptaminol		•	pentetrazol
•	4-methylpentan-2-amin (1,3-dimethylbutylamin)		•	hydrafinil (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon x xxxx analogy, xxxx. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• klonidin;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx kožního, xxxxxxx, xxxxxx nebo xxxxxx použití (např. xxxxxxxxxx, klonazolin, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x stimulancia zařazená xx Xxxxxxxxxxxxxx xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx v xxxx xxxxx: diamorfin (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx jejich xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 KANABINOIDY

ZAKÁZANÉ XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx přírodní x xxxxxxxxxx kanabinoidy xxxx xxxxxxxx, xxxx.

• x xxxxxx (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• přírodní x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx látky v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, perorální [včetně xxxxxxxxxx (např. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Jiné xxxxxxx xxxxxx (včetně xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx dávek a xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a xxx xx xx označeno xxxxxxxx (*) x Xxxx soutěž.

• lukostřelba (XX)*

• lyžování/snowboarding (FIS) – xxxxx xx xxxxxx, xxxxxxxxxxx xxxxx / X-xxxxx x xxxxxxxxx X-xxxxx / xxx xxx

• automobilový xxxxx (XXX)

• podvodní xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx potápění, xxxx harpunou x xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx disciplíny) (XXXX)

• xxxxx (WDF)

• xxxx (XXX)

• xxxxxxxx (XXX)

• střelba (ISSF, XXX)*

* xxxxxxxx xxxx Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx č. 2

Xxxxx xxxxxxxxxxx smlouvy x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x xxxx xxxxx xxx 5 mikrogramů x 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx v xxxx xxxxx xxx 150 xxxxxxxxxx x 1 xx.

³⁾ efedrin x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx v xxxx vyšší než 10 xxxxxxxxxx v 1 ml.

⁴⁾ epinefrin (xxxxxxxxx): xxxx zakázáno xxxxxxx podávání, např. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx anestetiky.

⁵⁾ bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: tyto xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx programu 2024 x xxxxxx považovány xx Xxxxxxxx látky.

Xxxxxxxxx

Xxxxxx xxxxxxx č. 19/2025 Sb. nabyl xxxxxxxxx xxxx 28.1.2024.

Znění xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx